10x Genomics Shares Rise to $79.10 as GF Value Stands at $18.34

10x Genomics Inc (TXG) shares advanced 3.3% to $79.10 on September 21, 2026, extending a one-year gain that spans a 52-week range from $11.16 to $80.11. The company remains unprofitable with negative cash flow, a fundamental reality that contrasts sharply with its current market valuation.

GuruFocus data indicates a significant divergence between the market price and intrinsic value, labeling the stock as significantly overvalued. This disconnect highlights a tension between short-term momentum and the underlying financial metrics of the business.

Valuation gap exceeds 300 percent

The current share price of $79.10 is 331.3% above the GF Value estimate of $18.34. This proprietary metric is derived from historical trading multiples and growth projections, serving as a directional warning for investors. For a company that is not yet generating positive earnings, this premium suggests substantial downside risk if market sentiment shifts away from speculative momentum.

Traditional price-to-earnings ratios are inapplicable due to the absence of profits, making the price-to-sales ratio a more relevant metric. TXG has historically traded at a median P/S of 10.3x, but the current premium implies that investors are pricing in growth that has not yet materialized in the company’s financial results.

Financial health shows mixed signals

The GF Score of 56 out of 100 reflects average overall performance with distinct strengths and weaknesses. The company scores 8 out of 10 for financial strength, indicating a solid balance sheet capable of withstanding operational challenges. This stability is offset by a valuation sub-score of 1 out of 10, which flags the current market price as extreme relative to fundamentals.

Profitability and momentum both rated 3 out of 10, underscoring the lack of current earnings generation and modest price action. Growth received a 6 out of 10, suggesting moderate expansion potential. These sub-scores combine to paint a picture of a financially resilient but operationally struggling entity that is currently priced for perfection.

Insiders sold $14.4 million in shares

Insider activity has been exclusively negative, with company insiders selling $14.4 million worth of shares over the past 12 months without any reported buying. This consistent offloading suggests a lack of confidence from those closest to the company’s daily operations and long-term prospects.

Institutional sentiment is similarly mixed, with nine gurus holding positions in TXG. While three added to their stakes, six trimmed their holdings in recent quarters. This balanced but cautious approach from professional investors aligns with the broader narrative of a company trading well above its estimated intrinsic value.